Please rotate your device

GET PROPEL

Stay Informed

You are leaving the HCP website

You are being directed to a third-party website. Please note that this third-party website is not controlled by PROPELOpens.com.

Thank you for visiting our site.

Continue
The first real-world evidence analysis on the impact of the PROPEL family of implants in CRS patients
CMR Publication

The use of PROPEL following sinus surgery may result in payer savings from reduced healthcare resource utilization.

Learn More

The use of PROPEL following sinus surgery may result in payer savings from reduced healthcare resource utilization

The first real-world evidence analysis on the impact of the PROPEL family of implants in CRS patients

STUDY DESIGN: A retrospective, observational cohort study that LEVERAGED a multisource database containing healthcare claims and EMT data in the US

A retrospective, observational cohort study including 3,966 adult patients with CRS with or without nasal polyps that assessed the impact of the PROPEL family of implants on healthcare resource usage, in the 18 months following sinus surgery.

Real-World Evidence Study Design

The first RWE study to evaluate the long-term impact of PROPEL family of implants on HCRU among CRS patients undergoing sinus surgery

A retrospective, observational cohort study*

PROPEL real world evidence
  • In order to compare cohorts of similar CRS disease severity propensity score (PS matching and exact matching was implemented
    • PS was calculated using logistic regression modeling for the probability of receiving an implant
    • Exact matching on the number of prior sinus surgeries and the presence of polyps prior to the index surgery

EMR, electronic medical record; HCRU, health care resource utilization.

*Leveraged a multisource database containing healthcare claims and EMR data in the US. The dataset used for this study is fully de-identified.

†Chi-square for binary variables and analysis of variance tests for continuous variables were applied to compare HCRU measures.

‡The logistic regression model included the following baseline variables: demographics (age, sex, race), presence of asthma and/or allergic rhinitis, overall comorbidity burden as measured by the Deyo-Charlson comorbidity index, year of surgery, duration of the baseline period, and facility type.

1. Hoffman V, et al. Curr Med Res Opin. 2022 Jan 20:1-7. doi: 10.1080/03007995.2021.2022874. Epub ahead of print.

Patient Population: A large (N=3966) RWE study in a diverse CRS patient population

PROPEL and non-PROPEL cohorts were well-balanced with nearly 10,700 total sinuses studied.

Real-World Evidence Patient Population

A large (N-3966) RWE study in a diverse CRS patient population

PROPEL real world evidence

COPD, chronic obstructive pulmonary disease; SD, standard deviation.

*Includes sleep apnea, nighttime awakening due to congestion, and snoring.

1. Hoffman V, et al. Curr Med Res Opin. 2022 Jan 20:1-7. doi: 10.1080/03007995.2021.2022874. Epub ahead of print.

Real-World Evidence Study Limitation

  • Real-world studies cannot definitively establish causality and are designed to evaluate associations
  • The data source did not allow for the identification of the specific sinuses in which the implants were placed
PROPEL real world evidence

1. Hoffman V, et al. Curr Med Res Opin. 2022 Jan 20:1-7. doi: 10.1080/03007995.2021.2022874. Epub ahead of print.

STUDY RESULTS

23% relative reduction in all-cause otolaryngology visits1

PROPEL cohort had a significantly lower percentage of all-cause otolaryngologist visits up to 18 months following sinus surgery

PROPEL real world evidence PROPEL real world evidence
  • PROPEL implants were associated with a 21% relative reduction in otolaryngologist visits at 0-6 months after sinus surgery, as compared to non-PROPEL users (44.6% vs 56.3%; P<0.001)
  • PROPEL implants were associated with a 22% relative reduction in otolaryngologist visits at >6-12 months after sinus surgery, as compared to non-PROPEL users (19.1% vs 24.5%; P<0.001)
  • PROPEL implants were associated with a 28% relative reduction in otolaryngologist visits at >12-18 months after sinus surgery, as compared to non-PROPEL users (13.8% vs 19.3%; P<0.001)
read the full publication

25% relative reduction in all-cause ER/urgent care visits1

PROPEL cohort had a lower percentage of all-cause ER/urgent care visits up to 18 months following sinus surgery

PROPEL real world evidence PROPEL real world evidence
  • PROPEL implants were associated with a 32% relative reduction in ER/urgent care visits at 0-6 months after sinus surgery, as compared to non-PROPEL users (3.4% vs 5.0%; P=0.012).
  • Difference did not reach significance at >6-12 months (4.2% vs 5.5%; P=0.054) and >12-18 months (4.5% vs 5.4%; P=0.189)
read the full publication

2% relative reduction in all-cause outpatient visits1

PROPEL cohort had a lower percentage of all-cause outpatient visits up to 18 months following sinus surgery

PROPEL real world evidence PROPEL real world evidence
  • PROPEL implants were associated with a 6% relative reduction in outpatient visits at 0-6 months after sinus surgery, as compared to non-PROPEL users (86.3% vs 91.8%; P<0.001).
  • Difference did not reach significance at >6-12 months (76.0% vs 78.1%; P=0.113) and >12-18 months (72.1% vs 73.1%; P=0.499)
read the full publication

11% relative reduction in sinus-related endoscopies

PROPEL cohort had a lower percentage of sinus-related endoscopies up to 18 months following sinus surgery

PROPEL real world evidence PROPEL real world evidence
  • PROPEL implants were associated with a 13% relative reduction in endoscopies at 0-6 months after sinus surgery, as compared to non-PROPEL users (32.4% vs 37.1%; P=0.002)
  • Difference did not reach significance at >6-12 months (16.6% vs 18.0%; P=0.257) and >12-18 months (11.8% vs 13.1%; P=0.229)
read the full publication

14% relative reduction in repeat sinus surgeries1

The proportion of repeat sinus surgeries up to 18 months following sinus surgery

PROPEL real world evidence PROPEL real world evidence
  • Although not statistically significant, fewer patients in the PROPEL cohort underwent repeat sinus surgery, as compared to the Non-PROPEL cohort

NS, not significant.

1. Hoffman V, et al. Curr Med Res Opin. 2022 Jan 20:1-7. doi: 10.1080/03007995.2021.2022874. Epub ahead of print

read the full publication

STUDY CONCLUSION

The use of PROPEL following sinus surgery may result in payer savings from reduced healthcare resource utilization

read the full publication

GET PROPEL

Stay Informed

This site is intended for healthcare professionals in the United States

Instructions for Use:

PROPEL PROPEL MINI PROPEL MINI WITH SDS PROPEL Contour

Instructions for Use (EU):

PROPEL PROPEL MINIPROPEL CONTOUR
Stay Informed

References

  1. Hoffman V, et al. Curr Med Res Opin. 2022 Jan 20:1-7. DOI: 10.1080/03007995.2021.2022874. Epub ahead of print.

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

©2022 Intersect ENT, Inc. All rights reserved. Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries. MPM-11549 Rev 7.0

The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/foreign patents, found at intersectent.com/patents.